BioCentury | Aug 14, 2020
Finance

Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

Qiagen to remain independent Qiagen N.V. (NYSE:QGEN; Xetra:QIA) said it terminated its agreement to be acquired by Thermo Fisher Scientific Inc. (NYSE:TMO) after only 47% of shares were tendered by Qiagen shareholders, well below the...
BioCentury | Aug 12, 2020
Regulation

After speedy approval on immunogenicity data, Russia readies Phase III study of COVID-19 vaccine ‘Sputnik’

The Ministry of Health of the Russian Federation has approved a COVID-19 vaccine under emergency rules based on immunogenicity rather than protection data.  While COVID-19 vaccine developers have been gathering safety and immune response data...
BioCentury | Aug 11, 2020
Emerging Company Profile

GentiBio: combining trio of platforms to enhance Treg therapies

GentiBio launched this summer with a suite of technologies to develop next-generation Treg cell therapies that overcome several of the modality’s historical shortcomings, including stability and specificity. The company, which is focused on autoimmune, alloimmune...
BioCentury | Aug 11, 2020
Deals

After Verrica deal in dermatological cancer, Lytix looks ahead to next-generation oncology product

Norwegian biotech Lytix has found a partner for its lead program in dermatological cancers, affording it the opportunity to continue that product’s development in additional indications while also moving ahead with a preclinical small molecule...
BioCentury | Aug 8, 2020
Management Tracks

PacBio shifts executive team; plus changes at CMAB, Valo, Alentis, Amwell and more

Pacific Biosciences of California Inc. (NASDAQ:PACB) announced a series of management changes Friday. Chairman Christian Henry will become president and CEO, effective Sept. 14. John Milligan, a member of the sequencing company’s board, will succeed...
BioCentury | Aug 8, 2020
Product Development

Asymptomatic COVID-19 testing pushes forward, with lessons from cancer

The growing demand for asymptomatic COVID-19 testing is shifting the conversation from one-time diagnosis to ongoing screening, and from single results to population outcomes. Companies moving the ball forward for early detection of cancer, some...
BioCentury | Aug 8, 2020
Product Development

Novavax secures multicountry access to COVID-19 vaccine

Building on its commitment to make its COVID-19 vaccine globally accessible, Novavax closed two partnerships this week to supply Japan, India and lower income countries with doses of NVX-CoV2373. The biotech plans to start a...
BioCentury | Aug 8, 2020
Product Development

Bringing COVID-19 vaccines to authorization faster through data sharing

Developers of leading COVID-19 vaccines won’t be able to meet global demand on their own, but they do have the power to accelerate global coverage by helping each other reach authorization and streamlining development for...
BioCentury | Aug 7, 2020
Management Tracks

First chief diversity officer for Alexion; plus changes at WuXi, Dicerna, Valneva, MeiraGTx, Anika and more

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) appointed Uzair Qadeer as its first chief diversity officer. Previously, he served the rare diseases company as VP, head of enterprise partnership. His appointment comes as BIO rolls out its BIOEquality...
BioCentury | Aug 6, 2020
Emerging Company Profile

T-knife: creating TCR factories with transgenic mice

Armed with a €66 million ($78.2 million) series A round, T-knife emerged from stealth Thursday with plans to bring four TCR therapies into clinical testing by 2022 using a transgenic mouse platform designed to generate...
Items per page:
1 - 10 of 10644
BioCentury | Aug 14, 2020
Finance

Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

Qiagen to remain independent Qiagen N.V. (NYSE:QGEN; Xetra:QIA) said it terminated its agreement to be acquired by Thermo Fisher Scientific Inc. (NYSE:TMO) after only 47% of shares were tendered by Qiagen shareholders, well below the...
BioCentury | Aug 12, 2020
Regulation

After speedy approval on immunogenicity data, Russia readies Phase III study of COVID-19 vaccine ‘Sputnik’

The Ministry of Health of the Russian Federation has approved a COVID-19 vaccine under emergency rules based on immunogenicity rather than protection data.  While COVID-19 vaccine developers have been gathering safety and immune response data...
BioCentury | Aug 11, 2020
Emerging Company Profile

GentiBio: combining trio of platforms to enhance Treg therapies

GentiBio launched this summer with a suite of technologies to develop next-generation Treg cell therapies that overcome several of the modality’s historical shortcomings, including stability and specificity. The company, which is focused on autoimmune, alloimmune...
BioCentury | Aug 11, 2020
Deals

After Verrica deal in dermatological cancer, Lytix looks ahead to next-generation oncology product

Norwegian biotech Lytix has found a partner for its lead program in dermatological cancers, affording it the opportunity to continue that product’s development in additional indications while also moving ahead with a preclinical small molecule...
BioCentury | Aug 8, 2020
Management Tracks

PacBio shifts executive team; plus changes at CMAB, Valo, Alentis, Amwell and more

Pacific Biosciences of California Inc. (NASDAQ:PACB) announced a series of management changes Friday. Chairman Christian Henry will become president and CEO, effective Sept. 14. John Milligan, a member of the sequencing company’s board, will succeed...
BioCentury | Aug 8, 2020
Product Development

Asymptomatic COVID-19 testing pushes forward, with lessons from cancer

The growing demand for asymptomatic COVID-19 testing is shifting the conversation from one-time diagnosis to ongoing screening, and from single results to population outcomes. Companies moving the ball forward for early detection of cancer, some...
BioCentury | Aug 8, 2020
Product Development

Novavax secures multicountry access to COVID-19 vaccine

Building on its commitment to make its COVID-19 vaccine globally accessible, Novavax closed two partnerships this week to supply Japan, India and lower income countries with doses of NVX-CoV2373. The biotech plans to start a...
BioCentury | Aug 8, 2020
Product Development

Bringing COVID-19 vaccines to authorization faster through data sharing

Developers of leading COVID-19 vaccines won’t be able to meet global demand on their own, but they do have the power to accelerate global coverage by helping each other reach authorization and streamlining development for...
BioCentury | Aug 7, 2020
Management Tracks

First chief diversity officer for Alexion; plus changes at WuXi, Dicerna, Valneva, MeiraGTx, Anika and more

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) appointed Uzair Qadeer as its first chief diversity officer. Previously, he served the rare diseases company as VP, head of enterprise partnership. His appointment comes as BIO rolls out its BIOEquality...
BioCentury | Aug 6, 2020
Emerging Company Profile

T-knife: creating TCR factories with transgenic mice

Armed with a €66 million ($78.2 million) series A round, T-knife emerged from stealth Thursday with plans to bring four TCR therapies into clinical testing by 2022 using a transgenic mouse platform designed to generate...
Items per page:
1 - 10 of 10644